Introduction
============

Diabetes mellitus (DM) is a chronic disease that currently affects 7.4 million people in Japan, and its prevalence is increasing.[@b1-jcm-2-2011-043] Considerable mortality,[@b2-jcm-2-2011-043],[@b3-jcm-2-2011-043] morbidity,[@b4-jcm-2-2011-043],[@b5-jcm-2-2011-043] and costs[@b6-jcm-2-2011-043],[@b7-jcm-2-2011-043] are associated with the condition. For example, the annual medical expenditure for diabetes care in Japan in 2007 was estimated to be more than 1,100 billion yen, which represented approximately 5% of Japan's healthcare costs, and the rise in expenditure for diabetes care was higher than that for any other disease. Each year, more than 10,000 DM patients start on hemodialysis and approximately 3,000 patients become blind. Stricter glycemic control is key in preventing the microvascular complications of diabetes and in reducing the risk of macrovascular diseases.[@b8-jcm-2-2011-043]--[@b13-jcm-2-2011-043] Because of progressive deficits in insulin secretion, approximately half the patients with DM require insulin therapy to achieve good glycemic control.[@b11-jcm-2-2011-043],[@b13-jcm-2-2011-043],[@b14-jcm-2-2011-043] However, a delay in starting insulin is often reported.[@b15-jcm-2-2011-043]--[@b17-jcm-2-2011-043] For example, Kobayashi et al reported that the hypoglycemic effect of insulin therapy was proportional to basal HbA~1c~ at the time of initiation of insulin and any delay in starting insulin resulted in disappointing outcomes.[@b18-jcm-2-2011-043] There are several reasons why starting on insulin may be delayed. First, patients are often reluctant to start insulin injections. Second, clinicians may be reluctant to start insulin therapy because it is a time-consuming process and they may lack appropriate resources.

Insulin is usually started on an inpatient basis or on an outpatient basis in secondary care. However, most patients are seen at the primary care level and it is reasonable that insulin therapy has expected to be initiated at the site of the clinical practice because of social and economic considerations. The present study was conducted to provide baseline information regarding the time and human resources required to start insulin therapy in diabetes clinics, as well as to provide relevant economic data.

Patients and Methods
====================

Study setting and patient selection
-----------------------------------

Eleven diabetes clinics with practicing diabetologists participated in the present study. The clinics were located across Japan and the study period was March--November 2003. A total of 355 new patients with Type 2 DM were registered at their first clinic visit and followed for 5 consecutive months. Of these patients, 313 who were not on insulin were defined as the non-insulin group, whereas the 42 who were on insulin were defined as the insulin group. Twenty-six patients were on insulin at the time of their first visit to the clinic, whereas the remaining 16 patients in the insulin group started on insulin therapy after their first clinic visit. The initiation of insulin was done on outpatient basis at each clinic.

At the time of the first clinic visit, each new patient completed a form that recorded background information and behavior, as described previously.[@b19-jcm-2-2011-043] After plasma glucose, HbA~1c~, and urinalysis examinations, patients were interviewed by a Certified Diabetes Educator (CDE) nurse to confirm the history and lifestyle information recorded on the form. The CDE nurse gave this information to a physician, along with the glucose, HbA~1c~, and urinalysis results for that day. The physician met the patient, assessed the state of the disease, the patient's lifestyle, and his/her knowledge of the disease, and then offered advice. At the end of the consultation, the physician arranged for the patient to have a one-on-one education session with a dietician or nurse on either the same day or at the next visit. When and to whom education had been delivered was assessed by a physician after consideration of glycemic control, lifestyle, obesity, and the stages of change according to the transtheoretical model.[@b20-jcm-2-2011-043] Plasma glucose and HbA~1c~ (as determined by HPLC and expressed as a JDS value which is equivalent to (NGSP value---0.4)) were measured onsite at each visit, or each month, for every DM patient.

Each clinic had, on average, 1.7 diabetologists, 4.5 nurses, 2.2 dietitians, and 4.1 clerks, and seven of the clinics also had one technician. At least three of the staff at each clinic were CDEs. Consultations with physicians required a prior appointment in six of the clinics, but not in the other five. The clinics saw an average of 60 patients/day and 840 DM patients/month. Six of the clinics provided free group education sessions outside consulting hours.

Collection of data regarding time and cost
------------------------------------------

During the study period, the time expended by the clinic for each visit was recorded using a form that documented the time taken by physicians for each consultation, by nurses to interview the patients and perform laboratory examinations, by dietitians to provide dietary counseling, and by nurses to provide patient education. The sum of the times taken for each of these steps was defined as total care time, whereas the sum of the times to provide dietary counseling and patient education (carried out by a nurse) was defined as education time. Only the time for counseling delivered on a one-on-one basis was measured. The fees charged by each of the clinics each month were determined on the basis of reimbursement claims during the study period.

The study protocol was approved by the ethical committee of the JDDM. All registered patients were informed about the study and consented to being observed during their visit.

Statistical analysis
--------------------

Data are expressed as the mean ± SD. In univariate analyses, Student's *t*-test for continuous data and Pearson's χ^2^ test for categorical data were used to determine differences in means and proportions. Pearson's correlation coefficient was used to measure the association between two variables. *P* \< 0.05 was considered significant. All statistical analyses were performed using SPSS software (SPSS Japan, Tokyo, Japan).

Results
=======

Clinical characteristics of the patients
----------------------------------------

The clinical characteristics of the patients in the insulin and non-insulin groups are given in [Table 1](#t1-jcm-2-2011-043){ref-type="table"}. In the non-insulin group, 40% of patients were newly diagnosed, compared with 24% in the insulin group. The proportion of smokers in both groups was 44%.

The mean age of patients in the insulin group was less than that of patients in the non-insulin group (*P* \< 0.05). The average duration of diabetes in the non-insulin and insulin groups was 4.8 and 9.2 years, respectively (*P* \< 0.0001). Within the insulin group, the average duration of diabetes for those already on insulin and those starting insulin after their first clinic visit was 11.7 and 4.4 years, respectively. The mean HbA~1c~ level in the non-insulin and insulin groups was 8.0% and 9.3%, respectively (*P* \< 0.01). Mean body mass index (BMI) was smaller and systolic blood pressure was significantly lower in the insulin group compared with the non-insulin group. However, there was no significant difference in total cholesterol levels between the two groups.

Time use during clinic visits
-----------------------------

Patients in the insulin group visited the clinic more frequently than did patients in the non-insulin group. There was no significant difference in the number of visits for patients in the insulin group who were already on insulin at the time of their first visit and those who started on insulin after their first visit ([Table 2](#t2-jcm-2-2011-043){ref-type="table"}).

The time spent by physicians consulting with patients was longer for the insulin group than the non-insulin group, especially for patients who started insulin therapy after their first visit. The times spent by nurses conducting interviews and performing laboratory examinations was nearly the same between the two groups during the first month. The time spent on patient education was significantly longer for patients starting insulin than for those already on insulin or not taking insulin. The mean total care time in the first month was significantly longer for patients in the insulin than the non-insulin group (138 vs. 100 min, respectively). The total care time tapered during the study period, but was still longer by approximately 12 min for the insulin group than the non-insulin group at the end of the 5-month period.

In the first month, dietary counseling was delivered to 33% and 43% of patients in the non-insulin and insulin groups, respectively ([Table 3](#t3-jcm-2-2011-043){ref-type="table"}). The counseling time was longer for patients in the non-insulin group than for those in the insulin group. Nurses provided counseling to 46% and 71% of patients in the non-insulin and insulin groups, respectively, during the first month, and the time spent with patients in the insulin group was much longer than that spent with patients in the non-insulin group throughout the study period. Patients who were starting insulin therapy after their first visit received more educational counseling from both the dietitian and nurse than did the other patients.

Economic data
-------------

Reimbursement for care is detailed in [Table 4](#t4-jcm-2-2011-043){ref-type="table"}. These figures do not include charges for medications and insulin. The reimbursement for the insulin group was approximately twice that of the non-insulin group in every month of the study. Under the Japanese medical system, charges associated with the self-monitoring of glucose levels and nurse counseling were covered for the insulin group, but not for the non-insulin group. Therefore, the reimbursement for expenses in addition to examinations was considered as an insulin-related expense. The total fee divided by total care time for the insulin group was approximately twice that for the non-insulin group throughout the study period, except for the total fee/min in the first and second months.

Clinical outcomes
-----------------

The mean HbA~1c~ level in the non-insulin group decreased from 8.0% at the first visit to 6.5% after 5 months, compared with a decrease in mean HbA~1c~ in the insulin group over the same time frame from 9.4% to 7.6% ([Table 5](#t5-jcm-2-2011-043){ref-type="table"}). In the group of patients who started insulin therapy after their first visit, the mean HbA~1c~ level improved better than in the group of patients continuing with insulin therapy, although HbA~1c~ levels in the latter group after 5 months were still higher than in the non-insulin group. The proportion of patients in the non-insulin group who achieved an HbA~1c~ ≤ 6.5% in the first month was 34%, which increased to 72% after 5 months (range 56%--88% across the 11 clinics). In comparison, 24% and 39% of patients in the insulin group achieved an HbA~1c~ ≤ 6.5% after 1 and 5 months, respectively.

Blood pressure in the non-insulin group decreased significantly between the first visit and the fifth month, but remained the same in the insulin group. Although total cholesterol levels decreased between the first and fifth months in both groups, the decrease was only significant for the non-insulin group ([Table 5](#t5-jcm-2-2011-043){ref-type="table"}). The proportion of patients who achieved their target systolic blood pressure increased in the non-insulin group over the 5 months of the study, but was unchanged in the insulin group ([Table 5](#t5-jcm-2-2011-043){ref-type="table"}). The BMI after 5 months was nearly the same as that on the first visit for both groups.

Discussion
==========

The present study has provided baseline data regarding the time and costs involved in the management of newly registered patients in diabetes clinics in Japan according to whether they are receiving insulin or non-insulin therapy. The time and resource utilization for patients receiving insulin therapy was approximately twice that for those receiving non-insulin therapy. In addition, patients receiving insulin therapy had 1.3-fold more clinic visits/month than patients not on insulin therapy. Compared with patients in the non-insulin group, the total time spent on patients who were either on insulin therapy at the time of their first clinic visit or who started insulin after their first visit was 1.4- and 1.7-fold greater, respectively, at the end of the first month. Although the time spent on patients in the insulin group decreased over the 5 months of the study, it remained consistently higher than that spent on patients in the non-insulin group (∼4 min). Furthermore, the time physicians spent consulting with patients was 2.5 min longer for the insulin group after 4 months. In previous studies, it has been reported that approximately 7 min is spent seeing outpatients with DM treated with medication,[@b19-jcm-2-2011-043],[@b21-jcm-2-2011-043]; thus, in the present study having to spend an additional 2.5 min with patients in the insulin compared with the non-insulin group may place a further burden on physicians. The time spent by nurses providing patient education was also longer for the insulin group than the non-insulin group, especially in the first 3 months. These data indicate that patients can become accustomed to administering insulin injections and self-monitoring glucose levels over a period of approximately 3 months, even though they are likely to need greater consultation than patients who are not on insulin throughout their treatment.

The total fee for the insulin group was approximately double (ie, 10,000 yen) that for the non-insulin group. However, the calculated fee for the insulin group included the costs of sensors and other equipment needed for glucose monitoring, as well as fees for the disposal of these medical devices, so that the actual fee for insulin care is only approximately half the reported fee. The additional costs in the insulin group were offset by reimbursements for education and support of insulin injections, and are thought to be reasonable considering the time expended on these patients, even though the costs remain higher than those in the non-insulin group.

For most patients in Japan, insulin therapy had been initiated on an inpatient basis. However, in recent times it has become increasingly difficult for patients to afford hospital admission to start insulin therapy. The costs associated with starting insulin as an inpatient (5--7 days hospitalization) have been reported to be fourfold greater in France[@b22-jcm-2-2011-043] and 10-fold greater in Germany[@b23-jcm-2-2011-043] compared with the costs of initiating insulin therapy on an outpatient basis. In these reports, equivalent glycemic control was achieved at 3 and 12 months, respectively,[@b22-jcm-2-2011-043],[@b23-jcm-2-2011-043] and the authors concluded that the initiation of insulin therapy on an outpatient basis was as safe and effective as starting insulin as an inpatient, and that it was very cost-effective.[@b22-jcm-2-2011-043],[@b23-jcm-2-2011-043]

In the present study, the HbA~1c~ improved from a mean of 9.4% to 7.6% in the insulin group, which was a slightly larger decrease than that seen in the non-insulin group (from 8.0% to 6.5%). There were no major hypoglycemic episodes recorded for any patient in either group in the present study. The BMI, which often increases in response to insulin therapy, did not increase in the present study, which is attributed to the quality of the self-care education provided by the CDE nurses and dietitians. However, the proportion of patients who achieved the glycemic goal (ie, HbA~1c~ ≤ 6.5%) was only 39% in the insulin group, compared with 72% in the non-insulin group. The basal HbA~1c~ in the group of patients who started insulin after their first clinic visit was as high as 9.5%, which reflects a delay in the initiation of insulin. It has been reported previously that the mean basal HbA~1c~ of patients who achieved HbA~1c~ ≤ 6.5% after 12 months insulin was 7.5%.[@b18-jcm-2-2011-043] The mean age of patients in the insulin group was less than that in the non-insulin group and stricter glycemic control was expected from the point of view of preventing DM-associated complications and health care expenditure. It has been reported previously that the total health care expenditure decreases following the initiation of insulin therapy, despite initial increased costs.[@b24-jcm-2-2011-043]

Delays in initiating insulin therapy can be caused by several factors. First, patients are often reluctant to inject insulin. In addition, physicians may be reluctant to start insulin therapy because of concerns regarding patient acceptance of injections, a lack of nurses to provide patient education, and more complex and time-consuming difficulties in the medical management of insulin treatment.[@b15-jcm-2-2011-043]--[@b17-jcm-2-2011-043],[@b25-jcm-2-2011-043] Furthermore, many clinicians traditionally only consider initiating insulin therapy in T2DM patients after treatment with oral glucose-lowering agents has failed.[@b25-jcm-2-2011-043] Many patients with T2DM are seen in primary care settings. When we weigh high priority against the need for tight glycemic control, it is evident that we need a more effective and efficient system in the community that can facilitate the initiation of insulin treatment earlier in those patients who require it by referring them to specialists and/or increasing the accessibility to CDEs.[@b16-jcm-2-2011-043],[@b17-jcm-2-2011-043],[@b26-jcm-2-2011-043],[@b27-jcm-2-2011-043]

There are some limitations to the present study. First, the sample size was small in the insulin group. The physicians participating in the study are specialists and the proportion of newly registered patients a year in the insulin group is not so small compared to that of general physician's clinics. However, it is still too small to evaluate the effect of the severity of glycemic control, duration of diabetes and complications which are the factors that are considered to affect the time and costs of the treatment. In addition, the education program was not standardized and differed between clinics, such that a relatively large standard deviation was obtained for the time spent educating patients.

In conclusion, the titration and initiation of insulin therapy for T2DM patients can be achieved safely and effectively at outpatient clinics. Although insulin therapy requires much more time and resources than non-insulin therapy, the initiation of insulin therapy on an outpatient basis remains a cost-effective option. The initiation of insulin should not be delayed when it is needed.
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BMI

:   body mass index;

CDE

:   certified diabetes educator;

DM

:   diabetes; HbA~1c~, glycated haemoglobin;

JDDM

:   Japan Diabetes Clinical Data Management study group;

OGLA

:   oral glucose-lowering agents.

###### 

Clinical characteristics of patients with and without insulin therapy.

  **Characteristics**            **Non-insulin group**   **Insulin group**                                                                                                           
  ------------------------------ ----------------------- ------------------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------
  n                              313                     42                                                            26                                                            16
  Sex (male/female)              197/116                 21/21                                                         14/12                                                         7/9
  Age (years)                    57.5 ± 12.3             51.7 ± 16.1[^‡^](#tfn2-jcm-2-2011-043){ref-type="table-fn"}   54.0 ± 15.9                                                   47.5 ± 16.0[^\*^](#tfn4-jcm-2-2011-043){ref-type="table-fn"}
  Duration of diabetes (years)   4.8 ± 5.9               9.2 ± 11.4[^‡^](#tfn2-jcm-2-2011-043){ref-type="table-fn"}    11.7 ± 12.6[^‡^](#tfn2-jcm-2-2011-043){ref-type="table-fn"}   4.4 ± 6.4
  HbA~1c~ (%)                    8.0 ± 2.0               9.3 ± 2.9[^†^](#tfn3-jcm-2-2011-043){ref-type="table-fn"}     9.3 ± 2.4[^†^](#tfn3-jcm-2-2011-043){ref-type="table-fn"}     9.5 ± 3.6
  SBP (mmHg)                     136 ± 22                128 ± 27[^‡^](#tfn2-jcm-2-2011-043){ref-type="table-fn"}      130 ± 27                                                      124 ± 25
  DBP (mmHg)                     79 ± 13                 76 ± 12                                                       74 ± 13                                                       79 ± 10
  BMI (kg/m^2^)                  24.2 ± 3.6              23.0 ± 3.5                                                    22.7 ± 2.9                                                    23.4 ± 4.4
  Tchol (mmol/l)                 5.5 ± 1.2               5.6 ± 1.1                                                     5.7 ± 1.2                                                     5.6 ± 1.0
  Smokers (%)                    44                      44                                                                                                                          
  Newly diagnosed patients (%)   40                      24[^‡^](#tfn2-jcm-2-2011-043){ref-type="table-fn"}                                                                          
  Combination of diseases (%)                                                                                                                                                        
    DM alone                     47                      59                                                                                                                          
    HT                           25                      12                                                                                                                          
    HL                           14                      17                                                                                                                          
    HT+HL                        14                      12                                                                                                                          

**Notes:** Data are the mean ± SD.

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.0001 compared with the non-insulin group.

**Abbreviations:** BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; HbA~1c~, glycated hemoglobin; HL, hyperlipidemia; HT, hypertension; SBP, systolic blood pressure; Tchol, total cholesterol.

###### 

Time use during monthly clinic visits for patients in the insulin and non-insulin groups.

                                                            **Time (months)**                                                                                                                                                                                        
  --------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------- --------------------------------------------------------------
  No. visits/month                                                                                                                                                                                                                                                   
    Non-insulin group                                       1.6 ± 0.8                                                      1.5 ± 0.7                                                     1.3 ± 0.5                                                     1.2 ± 0.4     1.2 ± 0.4
    Insulin group                                           2.2 ± 1.4[^†^](#tfn8-jcm-2-2011-043){ref-type="table-fn"}      1.9 ± 1.1[^\*^](#tfn7-jcm-2-2011-043){ref-type="table-fn"}    1.4 ± 0.6                                                     1.3 ± 0.7     1.5 ± 0.7[^†^](#tfn8-jcm-2-2011-043){ref-type="table-fn"}
      Ongoing therapy                                       2.1 ± 1.4                                                      1.9 ± 1.0                                                     1.6 ± 0.8                                                     1.4 ± 0.8     1.5 ± 0.6
      Therapy initiated                                     2.3 ± 1.0                                                      1.9 ± 1.0                                                     1.3 ± 0.5                                                     1.2 ± 0.4     1.4 ± 0.8
  Physician time (min)                                                                                                                                                                                                                                               
    Non-insulin group                                       20.5 ± 10.9                                                    11.3 ± 8.9                                                    7.6 ± 5.7                                                     7.1 ± 5.9     7.1 ± 6.7
    Insulin group                                           28.1 ± 18.2[^\*^](#tfn7-jcm-2-2011-043){ref-type="table-fn"}   17.2 ± 13.2[^†^](#tfn8-jcm-2-2011-043){ref-type="table-fn"}   9.7 ± 5.6[^\*^](#tfn7-jcm-2-2011-043){ref-type="table-fn"}    8.9 ± 5.5     9.5 ± 6.8[^\*^](#tfn7-jcm-2-2011-043){ref-type="table-fn"}
      Ongoing therapy                                       26.3 ± 19.9                                                    15.0 ± 11.4                                                   9.3 ± 5.2                                                     8.6 ± 5.5     7.5 ± 4.2
      Therapy initiated                                     36.2 ± 18.1                                                    20.8 ± 15.5                                                   10.6 ± 6.5                                                    9.3 ± 5.9     11.4 ± 8.9
  Time spent performing interviews and examinations (min)                                                                                                                                                                                                            
    Non-insulin                                             56.2 ± 38.4                                                    21.0 ± 18.1                                                   17.8 ± 15.9                                                   16.4 ± 14.6   15.5 ± 13.7
    Insulin                                                 92.2 ± 53.0[^†^](#tfn8-jcm-2-2011-043){ref-type="table-fn"}    38.6 ± 32.2[^†^](#tfn8-jcm-2-2011-043){ref-type="table-fn"}   21.6 ± 17.7                                                   23.7 ± 24.5   28.5 ± 30.4
      Ongoing therapy                                       86.4 ± 56.8                                                    45.3 ± 37.3                                                   24.9 ± 19.2                                                   23.5 ± 17.3   32.8 ± 35.5
      Therapy initiated                                     109.0 ± 46.5                                                   36.6 ± 26.5                                                   17.8 ± 15.9                                                   25.2 ± 32.3   24.5 ± 25.0
  Time spent educating patients (min)                                                                                                                                                                                                                                
    Non-insulin                                             23.7 ± 30.1                                                    18.8 ± 25.5                                                   10.6 ± 17.9                                                   6.3 ± 13.1    4.5 ± 11.2
    Insulin                                                 40.8 ± 42.9[^\*^](#tfn7-jcm-2-2011-043){ref-type="table-fn"}   23.7 ± 36.4                                                   7.8 ± 11.0                                                    7.8 ± 17.9    5.6 ± 13.0
      Ongoing therapy                                       27.8 ± 32.9                                                    18.7 ± 36.2                                                   4.4 ± 7.5                                                     4.3 ± 11.0    1.3 ± 5.6
      Therapy initiated                                     64.8 ± 47.7                                                    35.2 ± 34.7                                                   13.9 ± 13.8                                                   13.5 ± 25.2   11.0 ± 17.3
  Total care time (min)                                                                                                                                                                                                                                              
    Non-insulin                                             100.0 ± 60.7                                                   51.1 ± 35.2                                                   36.0 ± 24.7                                                   29.7 ± 20.9   27.1 ± 19.8
    Insulin                                                 137.8 ± 78.5[^†^](#tfn8-jcm-2-2011-043){ref-type="table-fn"}   63.9 ± 48.2                                                   34.6 ± 18.0                                                   36.2 ± 28.1   39.1 ± 33.6[^\*^](#tfn7-jcm-2-2011-043){ref-type="table-fn"}
      Ongoing therapy                                       104.3 ± 66.3                                                   62.3 ± 55.9                                                   35.1 ± 18.4                                                   35.2 ± 24.0   41.9 ± 37.7
      Therapy initiated                                     152.8 ± 66.2                                                   71.6 ± 43.4                                                   32.7 ± 16.9                                                   39.6 ± 32.9   39.1 ± 33.8
  Waiting time (min)                                                                                                                                                                                                                                                 
    Non-insulin                                             65.8 ± 49.8                                                    58.5 ± 43.6                                                   43.2 ± 30.6                                                   45.1 ± 34.4   44.7 ± 33.5
    Insulin                                                 94.1 ± 76.5[^\*^](#tfn7-jcm-2-2011-043){ref-type="table-fn"}   65.8 ± 52.3                                                   62.4 ± 43.0[^†^](#tfn8-jcm-2-2011-043){ref-type="table-fn"}   46.5 ± 37.9   59.1 ± 44.3[^\*^](#tfn7-jcm-2-2011-043){ref-type="table-fn"}
      Ongoing therapy                                       99.2 ± 91.0                                                    67.3 ± 56.2                                                   70.8 ± 50.4                                                   54.0 ± 43.3   64.2 ± 51.1
      Therapy initiated                                     84.5 ± 38.4                                                    63.4 ± 46.8                                                   47.2 ± 17.2                                                   29.6 ± 19.5   52.6 ± 34.7

**Notes:** Data are the mean ± SD.

*P* \< 0.05,

*P* \< 0.01 compared with the non-insulin group. The time spent educating patients is the sum of the time spent providing dietary counseling and education by nurses.

###### 

Delivery rate and time spent providing dietary counseling and education by nurses.

                               **Time (months)**                                                                                                                                                                                                                               
  ---------------------------- -------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------------- -------------
  Dietary counseling                                                                                                                                                                                                                                                           
    Non-insulin (OGLAs+diet)                                                                                                                                                                                                                                                   
      Delivery rate            32.6%                                                          37.7%                                                    26.2%                                                    16.3%                                                          10.5%
      Time (min)               46.0 ± 21.1                                                    40.2 ± 22.0                                              33.0 ± 18.0                                              29.6 ± 13.5                                                    25.7 ± 13.3
    Insulin                                                                                                                                                                                                                                                                    
      Delivery rate            43.2%                                                          26.7%                                                    15.4%                                                    14.0%                                                          5.1%
      Time (min)               36.6 ± 19.4                                                    36.1 ± 20.0                                              24.7 ± 8.1                                               25.0 ± 12.2                                                    29.0 ± 8.5
    Ongoing therapy                                                                                                                                                                                                                                                            
      Delivery rate            34.6%                                                          23.1%                                                    4.5%                                                     12.5%                                                          0.0%
      Time (min)               32.2 ± 16.3                                                    34.7 ± 16.4                                              18                                                       25.3 ± 17.0                                                    --
    Therapy initiated                                                                                                                                                                                                                                                          
      Delivery rate            50.0%                                                          37.5%                                                    41.7%                                                    21.4%                                                          12.5%
      Time (min)               49.3 ± 22.8                                                    37.5 ± 24.6                                              26.0 ± 8.3                                               24.7 ± 9.0                                                     29.0 ± 8.5
  Nurse education                                                                                                                                                                                                                                                              
    Non-insulin (OGLAs+diet)                                                                                                                                                                                                                                                   
      Delivery rate            45.7%                                                          18.9%                                                    11.0%                                                    10.5%                                                          9.6%
      Time (min)               19.3 ± 17.4                                                    18.9 ± 13.4                                              17.2 ± 12.4                                              14.0 ± 8.2                                                     18.6 ± 14.6
    Insulin                                                                                                                                                                                                                                                                    
      Delivery rate            70.5%[^†^](#tfn10-jcm-2-2011-043){ref-type="table-fn"}         44.4%[^‡^](#tfn11-jcm-2-2011-043){ref-type="table-fn"}   25.6%[^†^](#tfn10-jcm-2-2011-043){ref-type="table-fn"}   9.3%                                                           17.9%
      Time (min)               37.3 ± 26.4[^‡^](#tfn11-jcm-2-2011-043){ref-type="table-fn"}   31.3 ± 33.2                                              12.9 ± 8.3                                               47.3 ± 37.8[^‡^](#tfn11-jcm-2-2011-043){ref-type="table-fn"}   28.6 ± 17.4
    Ongoing therapy                                                                                                                                                                                                                                                            
      Delivery rate            57.7%                                                          26.9%                                                    27.3%                                                    4.1%                                                           4.1%
      Time (min)               28.9 ± 22.1                                                    32.3 ± 42.7                                              13.1 ± 6.8                                               27                                                             25
    Therapy initiated                                                                                                                                                                                                                                                          
      Delivery rate            92.9%                                                          68.8%                                                    25.0%                                                    14.3%                                                          25.0%
      Time (min)               47.0 ± 28.4[^†^](#tfn10-jcm-2-2011-043){ref-type="table-fn"}   30.7 ± 28.1                                              12.3 ± 12.7                                              57.5 ± 47.4                                                    29.5 ± 19.9

**Notes:** Data are the mean ± SD.

*P* \< 0.01,

*P* \< 0.001 compared with the non-insulin group. The delivery rate shows the percentage of patients in each group receiving dietary counseling and/or nurse education.

**Abbreviation:** OGLAs, oral glucose-lowering agents.

###### 

Reimbursement of costs for the care of diabetes with/without insulin therapy.

                                 **Time (months)**                                                                                                                                                                                                                                                    
  ------------------------------ ----------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------
  Total fees/month (yen)                                                                                                                                                                                                                                                                              
    Non-insulin (OGLAs+diet)     18885 ± 7214                                                      10366 ± 5988                                                     10798 ± 5089                                                     10207 ± 4253                                                     10433 ± 4606
    Insulin                      29660 ± 10968[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}   21697 ± 7507[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}   22933 ± 4886[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}   21654 ± 6234[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}   24012 ± 5538[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}
      Ongoing therapy            27893 ± 11802                                                     20819 ± 8720                                                     24221 ± 4952                                                     22942 ± 5818                                                     24806 ± 4919
      Therapy initiated          32941 ± 8646                                                      23123 ± 4881                                                     20572 ± 3926                                                     19446 ± 6514                                                     23019 ± 6247
  Care fees/month (yen)                                                                                                                                                                                                                                                                               
    Non-insulin (OGLAs+diet)     6173 ± 3970                                                       5247 ± 4007                                                      5977 ± 3880                                                      5606 ± 3380                                                      5532 ± 3455
    Insulin                      17135 ± 8806[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}    16371 ± 7005[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}   17619 ± 4017[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}   16575 ± 5253[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}   17765 ± 4906[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}
      Ongoing therapy            15706 ± 9192                                                      15168 ± 7982                                                     18433 ± 3924                                                     17444 ± 5329                                                     18043 ± 4352
      Therapy initiated          19791 ± 7646                                                      18325 ± 4622                                                     16127 ± 3873                                                     15086 ± 4950                                                     17418 ± 5651
  Examination fees/month (yen)                                                                                                                                                                                                                                                                        
    Non-insulin (OGLAs+diet)     13362 ± 5641                                                      5799 ± 3485                                                      5411 ± 2826                                                      5164 ± 2207                                                      5512 ± 2737
    Insulin                      12524 ± 4469                                                      5326 ± 2608                                                      5314 ± 2337                                                      5079 ± 2059                                                      6246 ± 2840
      Ongoing therapy            12188 ± 5071                                                      5651 ± 3186                                                      5788 ± 2781                                                      5499 ± 1614                                                      6763 ± 3273
      Therapy initiated          13150 ± 3133                                                      4798 ± 1094                                                      4445 ± 581                                                       4360 ± 2565                                                      5601 ± 2109
  Total fees/min (yen/min)                                                                                                                                                                                                                                                                            
    Non-insulin (OGLAs+diet)     250 ± 278                                                         312 ± 352                                                        469 ± 420                                                        530 ± 515                                                        583 ± 563
    Insulin                      303 ± 245                                                         474 ± 264[^‡^](#tfn15-jcm-2-2011-043){ref-type="table-fn"}       887 ± 630[^‡^](#tfn15-jcm-2-2011-043){ref-type="table-fn"}       1108 ± 1164[^†^](#tfn14-jcm-2-2011-043){ref-type="table-fn"}     925 ± 539[^‡^](#tfn15-jcm-2-2011-043){ref-type="table-fn"}
      Ongoing therapy            345 ± 295                                                         478 ± 251                                                        944 ± 731                                                        956 ± 688                                                        888 ± 475
      Therapy initiated          225 ± 54                                                          469 ± 293                                                        783 ± 390                                                        1368 ± 1704                                                      971 ± 623
  Care fees/min                                                                                                                                                                                                                                                                                       
    Non-insulin (OGLAs+diet)     77 ± 65                                                           156 ± 201                                                        269 ± 360                                                        288 ± 350                                                        307 ± 392
    Insulin                      172 ± 153[^‡^](#tfn15-jcm-2-2011-043){ref-type="table-fn"}        352 ± 221[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}      688 ± 484[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}      903 ± 1123[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}     690 ± 428[^\*^](#tfn16-jcm-2-2011-043){ref-type="table-fn"}
      Ongoing therapy            195 ± 184                                                         340 ± 213                                                        728 ± 554                                                        748 ± 582                                                        657 ± 398
      Therapy initiated          129 ± 43                                                          370 ± 239                                                        615 ± 326                                                        1168 ± 1693                                                      732 ± 473

**Notes:** Data are the mean ± SD.

*P* \< 0.01,

*P* \< 0.001,

*P* \< 0.00001 compared with the non-insulin group.

**Abbreviation:** OGLAs, oral glucose-lowering agents.

###### 

HbA~1c~, blood pressure, cholesterol values and body mass index for each month.

                                **Time (months)**                                                                                                                                                                                                                                                                                                                                              
  ----------------------------- ------------------------------------------------------------ ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  HbA~1c~ (%)                                                                                                                                                                                                                                                                                                                                                                                  
    Non-insulin (OGLAs+diet)    8.0 ± 1.9                                                    7.6 ± 1.7[^\*\*^](#tfn20-jcm-2-2011-043){ref-type="table-fn"}    7.1 ± 1.3[^\*\*\*\*^](#tfn22-jcm-2-2011-043){ref-type="table-fn"}                                                6.6 ± 1.0[^\*\*\*\*^](#tfn22-jcm-2-2011-043){ref-type="table-fn"}                                               6.5 ± 1.0[^\*\*\*\*^](#tfn22-jcm-2-2011-043){ref-type="table-fn"}
      % Patients who achieved   34%                                                          43%                                                              51%                                                                                                              70%                                                                                                             72%
      HbA~1c~ ≤ 6.5%                                                                                                                                                                                                                                                                                                                                                                           
    Insulin                     9.4 ± 2.9[^†^](#tfn24-jcm-2-2011-043){ref-type="table-fn"}   8.8 ± 2.4[^¶^](#tfn23-jcm-2-2011-043){ref-type="table-fn"}       8.0 ± 1.7^[∫∫](#tfn26-jcm-2-2011-043){ref-type="table-fn"},[\*\*](#tfn20-jcm-2-2011-043){ref-type="table-fn"}^   7.6 ± 2.0^[†](#tfn24-jcm-2-2011-043){ref-type="table-fn"},[\*\*](#tfn20-jcm-2-2011-043){ref-type="table-fn"}^   7.6 ± 1.5^[∫∫](#tfn26-jcm-2-2011-043){ref-type="table-fn"},[\*\*\*](#tfn21-jcm-2-2011-043){ref-type="table-fn"}^
      Ongoing therapy           9.2 ± 2.4                                                    9.1 ± 1.8                                                        8.1 ± 1.0                                                                                                        7.4 ± 1.2                                                                                                       7.7 ± 1.5
      Therapy initiated         9.5 ± 3.6                                                    8.5 ± 3.0                                                        7.8 ± 2.5                                                                                                        7.9 ± 3.1                                                                                                       7.5 ± 1.6
      % Patients who achieved   24%                                                          22%[^¶^](#tfn23-jcm-2-2011-043){ref-type="table-fn"}             21%[^‡^](#tfn25-jcm-2-2011-043){ref-type="table-fn"}                                                             39%[^‡^](#tfn25-jcm-2-2011-043){ref-type="table-fn"}                                                            39%[^‡^](#tfn25-jcm-2-2011-043){ref-type="table-fn"}
      HbA~1c~ ≤ 6.5%                                                                                                                                                                                                                                                                                                                                                                           
  SBP (mmHg)                                                                                                                                                                                                                                                                                                                                                                                   
    Non-insulin (OGLAs+diet)    136 ± 22                                                     130 ± 21[^\*\*\*^](#tfn21-jcm-2-2011-043){ref-type="table-fn"}   126 ± 21[^\*\*\*\*^](#tfn22-jcm-2-2011-043){ref-type="table-fn"}                                                 126 ± 20[^\*\*\*\*^](#tfn22-jcm-2-2011-043){ref-type="table-fn"}                                                127 ± 21[^\*\*\*\*^](#tfn22-jcm-2-2011-043){ref-type="table-fn"}
      % Patients who achieved   46%                                                          54%                                                              62%                                                                                                              65%                                                                                                             62%
      SBP ≤ 130 mmHg                                                                                                                                                                                                                                                                                                                                                                           
    Insulin                     128 ± 27[^‡^](#tfn25-jcm-2-2011-043){ref-type="table-fn"}    121 ± 18[^†^](#tfn24-jcm-2-2011-043){ref-type="table-fn"}        125 ± 16                                                                                                         127 ± 18                                                                                                        131 ± 22
      Ongoing therapy           130 ± 27                                                     123 ± 17                                                         127 ± 16                                                                                                         129 ± 18                                                                                                        130 ± 18
      Therapy initiated         124 ± 25                                                     118 ± 20                                                         122 ± 15                                                                                                         123 ± 18                                                                                                        132 ± 27
      % Patients who achieved   57%                                                          68%                                                              70%                                                                                                              52%                                                                                                             58%
      SBP ≤ 130 mmHg                                                                                                                                                                                                                                                                                                                                                                           
  DBP (mmHg)                                                                                                                                                                                                                                                                                                                                                                                   
    Non-insulin (OGLAs+diet)    80 ± 13                                                      76 ± 12[^\*\*\*^](#tfn21-jcm-2-2011-043){ref-type="table-fn"}    74 ± 11[^\*\*\*\*^](#tfn22-jcm-2-2011-043){ref-type="table-fn"}                                                  73 ± 12[^\*\*\*\*^](#tfn22-jcm-2-2011-043){ref-type="table-fn"}                                                 74 ± 13[^\*\*\*\*^](#tfn22-jcm-2-2011-043){ref-type="table-fn"}
    Insulin                     75 ± 12[^†^](#tfn24-jcm-2-2011-043){ref-type="table-fn"}     72 ± 11[^¶^](#tfn23-jcm-2-2011-043){ref-type="table-fn"}         75 ± 9                                                                                                           77 ± 9[^¶^](#tfn23-jcm-2-2011-043){ref-type="table-fn"}                                                         74 ± 12
      Ongoing therapy           74 ± 13                                                      73 ± 11                                                          76 ± 9                                                                                                           77 ± 9                                                                                                          74 ± 11
      Therapy initiated         79 ± 10                                                      71 ± 12                                                          73 ± 10                                                                                                          76 ± 11                                                                                                         74 ± 14
  Total cholesterol (mmol/L)                                                                                                                                                                                                                                                                                                                                                                   
    Non-insulin (OGLAs+diet)    5.5 ± 1.2                                                    5.3 ± 1.0[^\*^](#tfn19-jcm-2-2011-043){ref-type="table-fn"}      5.1 ± 1.1[^\*\*\*^](#tfn21-jcm-2-2011-043){ref-type="table-fn"}                                                  5.2 ± 1.0[^\*\*\*^](#tfn21-jcm-2-2011-043){ref-type="table-fn"}                                                 5.3 ± 0.8[^\*^](#tfn19-jcm-2-2011-043){ref-type="table-fn"}
    Insulin                     5.5 ± 1.2                                                    5.3 ± 1.0                                                        5.1 ± 1.1                                                                                                        5.2 ± 1.0                                                                                                       5.3 ± 0.8
      Ongoing therapy           5.6 ± 1.2                                                    5.1 ± 0.5                                                        5.8 ± 0.9                                                                                                        5.6 ± 0.9                                                                                                       5.5 ± 0.7
      Therapy initiated         5.5 ± 1.0                                                    5.5 ± 0.6                                                        4.8 ± 0.8                                                                                                        4.8                                                                                                             5.3 ± 1.2
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                                                                                                                                
    Non-insulin (OGLAs+diet)    24.2 ± 3.6                                                   24.5 ± 4.6                                                       23.9 ± 3.5                                                                                                       24.3 ± 3.8                                                                                                      24.0 ± 3.5
    Insulin                     23.0 ± 3.5                                                   23.7 ± 4.2                                                       23.6 ± 4.0                                                                                                       23.2 ± 3.7                                                                                                      23.6 ± 3.5
      Ongoing therapy           22.7 ± 2.9                                                   24.2 ± 4.1                                                       23.8 ± 4.4                                                                                                       23.6 ± 3.6                                                                                                      23.8 ± 3.8
      Therapy initiated         23.4 ± 4.4                                                   22.6 ± 4.5                                                       23.4 ± 4.0                                                                                                       22.6 ± 3.9                                                                                                      23.4 ± 3.4

**Notes:** Data are the mean ± SD.

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001,

*P* \< 0.00001 compared with the first month;

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001,

*P* \< 0.00001 compared with the non-insulin group.

**Abbreviations:** OGLAs, oral glucose-lowering agents; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.
